2013
Long-term disease control of ≥2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study.
Cohen E, Hong D, Pfister D, Salgia R, Burtness B, Cohen R, Ball D, Mehra R, Mangeshkar M, Yaron Y, Bentzien F, Kurzrock R. Long-term disease control of ≥2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study. Journal Of Clinical Oncology 2013, 31: 6090-6090. DOI: 10.1200/jco.2013.31.15_suppl.6090.Peer-Reviewed Original ResearchLong-term disease controlMetastatic medullary thyroid cancerMaximum-tolerated doseMetastatic MTCVascular endothelial growth factor receptor 2Disease controlDose reductionImportant new treatment optionMetastatic medullary thyroid carcinomaMedian final doseMucositis/stomatitisAdverse event profileAdvanced solid tumorsGrowth factor receptor 2Medullary thyroid cancerPhase I studiesTerm disease controlNew treatment optionsEndothelial growth factor receptor 2Medullary thyroid carcinomaFactor receptor 2MTC cohortExpansion cohortMinimum followDose modification
2010
Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303).
Wanebo H, Ghebremichael M, Burtness B, Ridge J, Spencer S, Rosen F, Hancock M, Tolba K, Forastiere A. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303). Journal Of Clinical Oncology 2010, 28: 5513-5513. DOI: 10.1200/jco.2010.28.15_suppl.5513.Peer-Reviewed Original Research